Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has reaffirmed its positive opinion by consensus for ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency has adopted a positive opinion for the label expansion of Fabhalta ...

MPA’s policy is consistent with Maine State Law," the response read. "The determination that MPA has violated Title IX first requires that MPA be beholden to Title IX due to receiving direct or ...

The CHMP has specifically backed Leqembi to treat mild cognitive impairment or mild dementia from Alzheimer’s but only for patients carrying one or no copy of the ApoE4 gene.

The U.S. Department of Health and Human Services (HHS) Office for Civil Rights (OCR) announced on Monday that the Maine Department of Education, the Maine Principals’ Association and Greely High ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the topical gene therapy be approved to treat wounds in DEB patients of all ages in either a healthcare setting or at ...

In January 2025, as part of its decision-making process, the EC asked the CHMP to consider information on the safety of lecanemab that became available after the adoption of the CHMP opinion in ...

The 2026 BMW iX now offers up to 364 miles of range with the 20-inch wheels. With the largest wheels, the facelifted iX xDrive60’s range drops to 318 miles. The top version delivers 536 hp and ...

Have you been itching to spec out your refreshed 2026 BMW iX facelift? Raging that German customers have been able to build their cars for weeks now while BMW hid it from people in the US?

Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a positive opinion and recommended granting a marketing a ...

The Committee for Medicinal Products for Human Use (CHMP) has also recommended J&J’s Stelara (ustekinumab) to treat paediatric patients weighing at least 40kg with moderately to severely active CD, ...